Novartis CEO feels heat on U.S. generics, Cosentyx drop

ZURICH (Reuters) - Swiss drugmaker Novartis' first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit.

from Reuters: Health https://ift.tt/2K4g1Bs